Myriad to Buy Back $200M in Shares | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Myriad Genetics announced after the close of the market on Monday that its board has approved a new $200 million stock repurchase program.

The board had previously approved a $100 million stock buyback program in March.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.